ライフサイエンスコーパス: coagulation disorder

1 antiplatelet therapy and anticoagulation or coagulation disorders).

2 ufficiency, single-ventricle physiology, and coagulation disorder.

3 rections and decisions in surgery and innate coagulation disorders.

4 r in characterization and treatment of blood coagulation disorders.

5 T) is associated with risk of thrombosis and coagulation disorders.

6 may have detrimental effects associated with coagulation disorders.

7 e associated with the end-stage of different coagulation disorders.

8 s, primary nocturnal enuresis, nocturia, and coagulation disorders.

9 ce in patients with F10 deficiency and other coagulation disorders.

10 The role of these molecules in the coagulation disorder and hemorrhagic syndrome caused by

11 Lonomia obliqua are often associated with a coagulation disorder and hemorrhagic syndrome in humans.

12 ing 220 plasma samples of patients suffering coagulation disorders and 80 plasma samples of non-patie

13 creased rate of hospital contacts because of coagulation disorders and cerebrovascular disease, espec

14 Coagulation disorders and reperfusion of ischemic myocar

15 ion warrants clinical study as a therapy for coagulation disorders and surgical or traumatic bleeding

16 rogens, 11 (20%) had a myeloproliferative or coagulation disorder, and in 7 (13%) the cause remained

17 ronary artery disease, 55 445 [21%] were for coagulation disorders, and 92 963 [35%] were for cerebro

18 ire ebolavirus (ZEBOV) leads to hypotension, coagulation disorders, and an impaired immune response a

19 the circulating blood, genetic and acquired coagulation disorders, and reduced antithrombotic or pro

20 mplications secondary to surgery, trauma, or coagulation disorders are important causes of morbidity

21 Myocardial infarction and coagulation disorders are leading causes of disability a

22 , before the application of gene therapy for coagulation disorders becomes widespread, several obstac

23 nd had progressive cholestasis and jaundice, coagulation disorders, bilateral ureterostomies, repetit

24 including Alzheimer's disease and dementia), coagulation disorders, cardiometabolic disorders, infect

25 Hemophilia A is a clinically important coagulation disorder caused by the lack or abnormality o

26 There was an observed increased rate of coagulation disorders following all 3 vaccines (AZD1222:

27 casts new light on our understanding of the coagulation disorder found in P. falciparum infection.

28 Persons with inherited coagulation disorders have high rates of HCV and HIV-1 i

29 This rational approach, applicable to other coagulation disorders, helps with interpreting the poor

30 proven efficacy in treating inflammatory and coagulation disorders in preclinical and clinical studie

31 using blood samples from patients with (anti)coagulation disorders indicated characteristic defects i

32 DAH may result from coagulation disorders, inhaled toxins, or infections.

33 n in its clinical application to the complex coagulation disorders of acute and chronic liver disease

34 ctionated heparin are used globally to treat coagulation disorders on an outpatient basis.

35 s, were pregnant, had a known immunologic or coagulation disorder, or were receiving prehospital anti

36 contacts because of coronary artery disease, coagulation disorders, or cerebrovascular disease betwee

37 spital contacts for coronary artery disease, coagulation disorders, or cerebrovascular disease in a 2

38 80 years without uncontrolled comorbidities, coagulation disorders, pregnancy or breastfeeding, recen

39 FVIII, FIX, FX, FXI, and FXIII, called rare coagulation disorders (RCDs), may result in coagulopathi

40 rove the treatment of life-threatening acute coagulation disorders, such as SIC.

41 factor (TF) is thought to play a role in the coagulation disorders that characterize filoviral infect

42 cently identified a class of diseases--blood coagulation disorders--that were associated with a 14-fo

43 used in the ICU have the potential to cause coagulation disorders, the exact incidence will vary bas

44 cific vessel development, paving the way for coagulation disorder therapeutics.

45 plement-activation disorders) and history of coagulation disorders (thrombocytopenia, thrombosis and

46 tory mediators and markers of autoimmune and coagulation disorders with cerebral palsy (CP), examinin